Long-term Remission in Schizophrenia and Schizoaffective Disorder: Results from the Risperidone Long-acting Injectable Versus Quetiapine Relapse Prevention Trial (constatre) [PDF]
, 2009 Enrico Smeraldi +6 more
openalex +1 more source
Biomaterial Strategies for Targeted Intracellular Delivery to Phagocytes
Advanced Functional Materials, Volume 36, Issue 1, 2 January 2026.Phagocytes are essential to a functional immune system, and their behavior defines disease outcomes. Engineered particles offer a strategic opportunity to target phagocytes, harnessing inflammatory modulation in disease. By tuning features like size, shape, and surface, these systems can modulate immune responses and improve targeted treatment for a ...
Kaitlyn E. Woodworth +2 more
wiley +1 more source
Comparison of the effect of lithium plus quetiapine with lithium plus risperidone in children and adolescents with bipolar I disorder: a randomized clinical trial [PDF]
, 2017 Nastaran Habibi +2 more
openalex +1 more source
Association Between Hippocampal Subfields and Clinical Symptoms of First-Episode and Drug Naive Schizophrenia Patients During 12 Weeks of Risperidone Treatment [PDF]
, 2022 Xiaoe Lang +7 more
openalex +1 more source
Brain and Behavior, Volume 16, Issue 1, January 2026.An overview of the mechanism of action, clinical trials, and classical findings of KarXT for the management of psychotic symptoms in patients with schizophrenia and alzheimer's disease. ABSTRACT Background Acute psychotic symptoms like delusions and hallucinations are of major concern while treating patients with schizophrenia and alzheimer's psychosis,
Ashir Kanwal +7 more
wiley +1 more source
Risperidone ISM: review and update of its usefulness in all phases of schizophrenia
Therapeutic Advances in PsychopharmacologyOne of the most important challenges in the management of patients with schizophrenia is to ensure adherence to antipsychotic treatment. The contribution of long-acting injectables (LAI) is undeniable in this matter, but there are still some unmet ...
Thomas Messer +3 more
doaj +1 more source
Use of monthly extended-release risperidone injection in schizophrenia: clinical experience
European PsychiatryIntroduction Monthly extended-release injectable risperidone is the new antipsychotic formulation of risperidone available in doses of 75 mg and 100 mg, approved for the treatment of schizophrenia.
E. de la Fuente Ruiz +3 more
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 1, January 2026.ABSTRACT Burning mouth syndrome (BMS) is a chronic pain condition characterized by persistent intraoral burning without an identifiable cause, predominantly affecting postmenopausal women. We present a unique case of a 63‐year‐old Ethiopian woman exhibiting a distinctive triad of BMS, vulvodynia, and progressive cognitive decline, an association not ...
Rachel Annam +2 more
wiley +1 more source
Idiopathic granulomatous mastitis associated with risperidone-induced hyperprolactinemia [PDF]
, 2012 Chih‐Hsun Lin +3 more
openalex +1 more source
Clinical Case Reports, Volume 14, Issue 1, January 2026.ABSTRACT The management of treatment‐resistant erotomania in patients with epilepsy requires a cautious pharmacological approach. This case demonstrates that replacing carbamazepine with valproic acid enabled the safe initiation of clozapine, resulting in resolution of erotomanic delusions while maintaining effective seizure control.
Fateme Roham +4 more
wiley +1 more source